Tumor Immunology

You have full text access to this OnlineOpen article

Humanization and characterization of the anti-HLA-DR antibody 1D10†

  1. Sheri A. Kostelny1,
  2. Brian K. Link2,
  3. J. Yun Tso1,
  4. Max Vasquez1,
  5. Brett H. Jorgensen1,
  6. Hong Wang1,
  7. William C. Hall3,
  8. George J. Weiner2,‡,§,*

Article first published online: 22 MAY 2001

DOI: 10.1002/ijc.1366

Issue

International Journal of Cancer

International Journal of Cancer

Volume 93, Issue 4, pages 556–565, 15 August 2001

Additional Information

How to Cite

Kostelny, S. A., Link, B. K., Tso, J. Y., Vasquez, M., Jorgensen, B. H., Wang, H., Hall, W. C. and Weiner, G. J. (2001), Humanization and characterization of the anti-HLA-DR antibody 1D10. Int. J. Cancer, 93: 556–565. doi: 10.1002/ijc.1366

Author Information

  1. 1

    Protein Design Labs, Inc., Fremont, CA, USA

  2. 2

    Holden Comprehensive Cancer Center and Department of Internal Medicine, University of Iowa, Iowa City, IA, USA

  3. 3

    Pathology Associates International, Frederick, MD, USA

  1. ‡

    Fax: +319-353-8988

  2. §

    G.J.W. has a financial interest in the 1D10 antibody.

*Holden Comprehensive Cancer Center, 5970Z JPP, University of Iowa, Iowa City, IA 52242, USA

  1. †

    The sequences reported in this report have been deposited in the GenBank data base (accession nos. AF281860 and AF281861).

  2. ‡

    Fax: +319-353-8988

  3. §

    G.J.W. has a financial interest in the 1D10 antibody.

Publication History

  1. Issue published online: 22 JUL 2001
  2. Article first published online: 22 MAY 2001
  3. Manuscript Accepted: 23 MAR 2001
  4. Manuscript Revised: 12 MAR 2001
  5. Manuscript Received: 29 NOV 2000

Funded by

  • Veterans Administration
  • US Public Health Service (GCRC). Grant Number: M01 RR00059
  • Protein Design Labs, Inc.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (216K)

REFERENCES

  • 1
    McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16: 2825–33.
  • 2
    Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 998;91: 1644–52.
  • 3
    Taji H, Kagami Y, Okada Y, Andou M, Nishi Y, Saito H, et al. Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Jpn J Cancer Res 1998;89: 748–56.
  • 4
    Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92: 1927–32.
  • 5
    Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14: 1974–81.
  • 6
    Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles TM, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996;2: 457–70.
  • 7
    Wahl RL, Zasadny KR, MacFarlane D, Francis IR, Ross CW, Estes J, et al. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. J Nucl Med 1998;39: 21S–7S.
  • 8
    Vose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, et al. Multicenter phase II study of Iodine-131 tositumomab for chemotherapy-relapsing/refractory low grade and transformed low grade B-cell non-Hodgkin's lymphoma. J Clin Oncol 2000;181: 1316–23.
  • 9
    Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17: 3793–803.
  • 10
    Witzig TE, White CA, Gordon LI, Murray JA, Wiseman GA, Czuczman MS, et al. Prospective randomized controlled study of Zevalin (IDEC-Y2B8) radioimmunotherapy compared to rituximab immunotherapy for B-cell NHL: report of interim results. Blood 1999;94: 631a.
  • 11
    Tuscano JM, Riva A, Toscano SN, Tedder TF, Kehrl JH. CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade. Blood 1999;94: 1382–92.
  • 12
    Leonard JP, Coleman M, Schuster MW, Feldman EJ, Chadburn A, Ely S, et al. Immunotherapy of NHL with epratuzumab (anti-CD22 monoclonal antibody): excellent tolerability with objective responses. Proc Am Soc Clin Oncol 2000;19: 60a.
  • 13
    Davis TA, Maloney DG, Czerwinski DK, Liles TM, Levy R. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood 1998;92: 1184–90.
  • 14
    Levy R, Miller RA. Therapy of lymphoma directed at idiotypes. J Natl Cancer Inst Monogr 1990;10: 61–8.
  • 15
    Epstein AL, Marder RJ, Winter JN, Stathopoulos E, Chen F-M, Parker JM, et al. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 1987;47: 830–40.
  • 16
    Hu E, Epstein AL, Naeve GS, Gill I, Martin S, Sherrod A, et al. A phase 1a clinical trial of LYM-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies. Hematol Oncol 1989;7: 155–66.
    Direct Link:
  • 17
    Gingrich RD, Dahle CE, Hoskins KF, Senneff MJ. Identification and Characterization of a new surface membrane antigen found predominantly on malignant B lymphocytes. Blood 1990;75: 2375–87.
  • 18
    Kostelny SK, Cole MS, Tso JY. Formation of a bispecific antibody by the use of leucine zippers. J Immunol 1992;148: 1547–53.
  • 19
    Tso JY, Wang SL, Levin W, Hakimi J. Preparation of a bispecific F(ab′)2 targeted to the human IL-2 receptor. J Hematother 1995;4: 389–94.
  • 20
    Co MS, Avadalovic NM, Caron PC, Avadalovic MV, Scheinberg DA, Queen C. Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol 1992;148: 1149–54.
  • 21
    Levitt M. Molecular dynamics of native protein. 1. Computer simulation of trajectories. J Mol Biol 1983;168: 595–620.
  • 22
    Zilber B, Scherf T, Levitt M, Anglister J. NMR-derived model for a peptide-antibody complex. Biochemistry 1990;29: 10032–41.
  • 23
    Glaser SM, Vasquez M, Payne PW, Schneider WP. Dissection of the combining site in a humanized anti-Tac antibody. J Immunol 1992;149: 2607–14.
  • 24
    He XY, Xu Z, Melrose J, Mullowney A, Vasquez M, Queen C, et al. Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P-selectin. J Immunol 1998;160: 1029–35.
  • 25
    Cole MS, Anasetti C, Tso JY. Human IgG2 variants of chimeric anti-CD3 are non-mitogenic to T cells. J Immunol 1997;159: 3613–21.
  • 26
    Ashfield R, Enriquez-Harris P, Proudfoot NJ. Transcriptional termination between the closely linked human complement genes C2 and factor for C2 and c-myc. EMBO J 1991;10: 4197–207.
  • 27
    Mulligan RC, Berg P. Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribyltransferase. Proc Natl Acad Sci U S A 1981;78: 2072–6.
  • 28
    Scatchard G. The attractions of small proteins for small molecules and ions. Ann NY Acad Sci 1949;51: 660–72.
    Direct Link:
  • 29
    Woodle ES, Thistlethwaite JR, Jolloffe LK, Zivin RA, Collins A, Adair JR, et al. Humanized OKT3 antibodies: successful transfer of immune modulating properties and iodotype expression. J Immunol 1992;148: 2756–63.
  • 30
    Fu XT, Karr RW. HLA-DR alpha chain residues located on the outer loops are involved in nonpolymorphic and polymorphic antibody-binding epitopes. Hum Immunol 1994;39: 253–60.
  • 31
    Levy R, Dilley J, Fox RI, Warnke R. A human thymus leukemia antigen defined by hybridoma monoclonal antibodies. Proc Natl Acad Sci U S A 1979;76: 6552–8.
  • 32
    Hill CM, Liu A, Marshall KW, Mayer J, Jorgensen B, Yuan B, et al. Exploration of requirements for peptide binding to HLA DRB1*0101 and DRB1*0401. J Immunol 1994;152: 2890–8.
  • 33
    Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A 1989;86: 10029–33.
  • 34
    Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. Sequences of proteins of immunological interest. 5th ed. Bethesda, MD: U.S. Department of Health and Human Services, 1991:1137.
  • 35
    Klohe EP, Watts R, Bahl M, Alber C, Yu WY, Anderson R, et al. Analysis of the molecular specificities of anti-class II monoclonal antibodies by using L cell transfectants expressing HLA class II molecules. J Immunol 1988;141: 2158–64.
  • 36
    Shackelford DA, Lampson LA, Strominger JL. Analysis of HLA-DR antigens by using monoclonal antibodies: recognition of conformational differences in biosynthetic intermediates. J Immunol 1981;127: 1403–10.
  • 37
    Elsasser D, Valerius T, Repp R, Weiner GJ, Deo Y, Kalden JR, et al. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood 1996;87: 3803–12.
  • 38
    Rose LM, Gunasekera AH, Denardo SJ, Denardo GL, Meares CF. Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol Immunother 1997;43: 26–30.
  • 39
    Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res 1992;52: 6761–7.
  • 40
    Higaki Y, Hata D, Kanazashi S, Horiguchi Y, Yamaoka K, Ohshima Y, et al. Mechanisms involved in the inhibition of growth of a human B lymphoma cell line, B104, by anti-MHC class II antibodies. Immunol Cell Biol 1994;72: 205–14.
  • 41
    Newell MK, Vanderwall J, Beard KS, Freed JH. Ligation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes. Proc Natl Acad Sci U S A 1993;90: 10459–63.
  • 42
    Truman JP, Choqueux C, Tschopp J, Vedrenne J, Le Deist F, Charron D, et al. HLA class II-mediated death is induced via Fas/Fas ligand interactions in human splenic B lymphocytes. Blood 1997;89: 1996–2007.
  • 43
    Truman JP, Ericson ML, Choqueux-Seebold CJ, Charron DJ, Mooney NA. Lymphocyte programmed cell death is mediated via HLA class II DR. Int Immunol 1994;6: 887–96.
  • 44
    Yoshino T, Cao L, Nishiuchi R, Matsuo Y, Yamadori I, Kondo E, et al. Ligation of HLA class II molecules promotes sensitivity to CD95 (Fas antigen, APO-1)-mediated apoptosis. Eur J Immunol 1995;26: 2190–4.
    Direct Link:
  • 45
    Nadler LM, Ritz J, Hardy R, Pesando JM, Schlossman SF, Stashenko P. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest 1981;67: 134–40.
  • 46
    Rose LM, Deng CT, Scott SL, Xiong CY, Lamborn KR, Gumerlock PH, et al. Critical Lym-1 binding residues on polymorphic HLA-DR molecules. Mol Immunol 1999;36: 789–97.
  • 47
    Bruggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987;166: 1351–61.
  • 48
    Greenwood J, Clark M, Waldmann H. Structural motifs involved in human IgG antibody effector functions. Eur J Immunol 1993;23: 1098–104.
    Direct Link:
  • 49
    Schlimok G, Riethmuller G, Pantel K, Fackler-Schwalbe I, Eisenberg J, Blythman H, et al. Tumor cell cytotoxicity induced in patients by a murine monoclonal antibody against the Lewis Y antigen. Proc Annu Meet Am Soc Clin Oncol 1991;10: 212.
  • 50
    Vuist WM, Levy R, Maloney DG. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. Blood 1994;83: 899–906.
  • 51
    Link BK, Wang H, Byrd JC, Leonard JP, Davis TA, Hall WC, et al. Phase I trial of humanized 1D10 (Hu1D10) monoclonal antibody targeting class II molecules in patients with relapsed lymphoma. Proc Am Soc Clin Oncol 2000;19: 86a.
View Full Article (HTML) Get PDF (216K)